Literature DB >> 2848196

Oncogenic potential of bcl-2 demonstrated by gene transfer.

J C Reed1, M Cuddy, T Slabiak, C M Croce, P C Nowell.   

Abstract

Follicular lymphoma is the most common human B-cell malignancy in the United States and Western Europe. Most of the tumours contain t(14;18) chromosome translocations involving the human bcl-2 gene. Translocation of bcl-2 sequences from chromosome 18 into the transcriptionally active immunoglobulin locus at chromosome band 14q32 in B cells deregulates bcl-2 gene expression, resulting in the accumulation of high levels of bcl-2 messenger. Human bcl-2 transcripts generate two proteins, p26 bcl-2-alpha and p22 bcl-2-beta, by virtue of alternative splice-site selection. Both proteins have in common their first 196 NH2-terminal amino acids but share little similarity with other sequences in a data bank. Although the biological and biochemical functions of bcl-2 are unknown, recent subcellular localization studies indicate that p26 bcl-2-alpha associates with cellular membranes, consistent with a stretch of hydrophobic amino acids in its carboxy terminus. The bcl-2 gene may represent a novel oncogene having no known retroviral counterpart. Here we demonstrate the oncogenic potential of bcl-2 through a gene transfer approach.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2848196     DOI: 10.1038/336259a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  44 in total

1.  Role of bcl-2 in Epstein-Barr virus-induced malignant conversion of Burkitt's lymphoma cell line Akata.

Authors:  J Komano; K Takada
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

Review 2.  Redox mechanisms of cytoprotection by Bcl-2.

Authors:  Alicia J Kowaltowski; Gary Fiskum
Journal:  Antioxid Redox Signal       Date:  2005 Mar-Apr       Impact factor: 8.401

3.  Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.

Authors:  Mai Nguyen; Richard C Marcellus; Anne Roulston; Mark Watson; Lucile Serfass; S R Murthy Madiraju; Daniel Goulet; Jean Viallet; Laurent Bélec; Xavier Billot; Stephane Acoca; Enrico Purisima; Adrian Wiegmans; Leonie Cluse; Ricky W Johnstone; Pierre Beauparlant; Gordon C Shore
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-26       Impact factor: 11.205

4.  BHRF1, the Epstein-Barr virus gene with homology to Bc12, is dispensable for B-lymphocyte transformation and virus replication.

Authors:  A Marchini; B Tomkinson; J I Cohen; E Kieff
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

5.  Complementation by BCL2 and C-HA-RAS oncogenes in malignant transformation of rat embryo fibroblasts.

Authors:  J C Reed; S Haldar; C M Croce; M P Cuddy
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

6.  The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737.

Authors:  Mariana Boiani; Cristina Daniel; Xueyuan Liu; Michael D Hogarty; Lawrence J Marnett
Journal:  J Biol Chem       Date:  2013-01-22       Impact factor: 5.157

7.  Microarray analysis of B-cell lymphoma cell lines with the t(14;18).

Authors:  Ryan S Robetorye; Sandra D Bohling; John W Morgan; G Chris Fillmore; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Mol Diagn       Date:  2002-08       Impact factor: 5.568

Review 8.  Finally, An Apoptosis-Targeting Therapeutic for Cancer.

Authors:  Carlo M Croce; John C Reed
Journal:  Cancer Res       Date:  2016-09-30       Impact factor: 12.701

9.  Anti-apoptotic protein Bcl-2 interacts with and destabilizes the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA).

Authors:  Elena S Dremina; Victor S Sharov; Keshava Kumar; Asma Zaidi; Elias K Michaelis; Christian Schöneich
Journal:  Biochem J       Date:  2004-10-15       Impact factor: 3.857

10.  Bc1-2 protects mice against fatal alphavirus encephalitis.

Authors:  B Levine; J E Goldman; H H Jiang; D E Griffin; J M Hardwick
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.